



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Brinzolamide

Item No. 11660

CAS Registry No.: 138890-62-7
Formal Name: 4R-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-1,1-dioxide-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide
Synonym: AL 4862
MF: C₁₂H₂₁N₃O₅S₃
FW: 383.5
Purity: ≥98%
UV/Vis.: λ_{max}: 253 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Brinzolamide is supplied as a crystalline solid. A stock solution may be made by dissolving the brinzolamide in the solvent of choice, which should be purged with an inert gas. Brinzolamide is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of brinzolamide in these solvents is approximately 30 mg/ml.

Brinzolamide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, brinzolamide should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Brinzolamide has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC₅₀s = 3.19 and 45.3 nM, respectively).¹ It is selective for CAII and CAIV over CAI (IC₅₀ = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.

Reference

1. DeSantis, L. Preclinical overview of brinzolamide. *Surv. Ophthalmol.* 44 (Suppl. 2), S119-S129 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM